# US 2026/0265380 A1 · Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0265380 A1
- Document ID: US20260265380A1
- Status: Published application
- Kind: A1
- Application number: 19/685,509
- Filed: 2026-05-22
- Published: 2026-09-10
- Earliest claimed: 2020-06-03
- Assignees: Mv Biotherapeutics SA; Institute for Research in Biomedicine
- Applicants: Mv Biotherapeutics SA; Institute for Research In Biomedicine
- Inventors: Fabio GRASSI; Benedetta DE PONTE CONTI
- Web page: https://patentgrep.com/patent/US20260265380A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- C12N 9/16: acting on ester bonds (3.1)
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 39/0011: {Cancer antigens}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C12N 9/14: Hydrolases (3)
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 2039/5156: {expressing foreign proteins}
- A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells}
- A61K 2039/55516: {Proteins; Peptides}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides a combination of (i) an immune checkpoint modulator and (ii) an ATP hydrolyzing enzyme, a nucleic acid encoding an ATP hydrolyzing enzyme, or host cells, microorganisms or viral particles comprising such nucleic acids encoding an ATP hydrolyzing enzyme. The combination may be used in medicine, in particular in the treatment of cancer, for example in cancer immunotherapy.

## Claims

### Claim 1

A method for reducing the risk of occurrence, treating, ameliorating, or reducing cancer or initiating, enhancing or prolonging an anti-tumor-response in a subject in need thereof, comprising administering to the subject a combination of
(i) an immune checkpoint modulator; and
(ii) (a) an ATP hydrolyzing enzyme,
(b) a nucleic acid comprising a polynucleotide encoding the ATP hydrolyzing enzyme,
(c) a host cell comprising the nucleic acid,
(d) a microorganism comprising the nucleic acid, or
(e) a viral particle comprising the nucleic acid
wherein the ATP hydrolyzing enzyme is apyrase.

### Claim 2 (depends on 1)

The method of claim 1, wherein the ATP hydrolyzing enzyme is not endogenous CD39.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ATP hydrolyzing enzyme is a soluble ATP hydrolyzing enzyme.

### Claim 4 (depends on 1)

The method of claim 1, wherein the apyrase is a bacterial apyrase or a plant apyrase.

### Claim 5 (depends on 1)

The method of claim 1, wherein the ATP hydrolyzing enzyme comprises an amino acid sequence as set forth in SEQ ID NO: 1 or a sequence variant thereof having at least 70%, 80% or 90% sequence identity.

### Claim 6 (depends on 1)

The method of claim 1, wherein the method comprises administering to the subject a combination of
(i) the immune checkpoint modulator; and
(ii) the nucleic acid comprising the polynucleotide encoding the ATP hydrolyzing enzyme.

### Claim 7 (depends on 6)

The method of claim 6, wherein the nucleic acid comprising the polynucleotide encoding the ATP hydrolyzing enzyme is a vector.

### Claim 8 (depends on 6)

The method of claim 6, wherein the nucleic acid further comprises heterologous elements for (heterologous) expression of the ATP hydrolyzing enzyme.

### Claim 9 (depends on 1)

The method of claim 1, wherein the method comprises administering to the subject a combination of
(i) the immune checkpoint modulator; and
(ii) the host cell comprising the nucleic acid.

### Claim 10 (depends on 9)

The method of claim 9, wherein the host cell is a prokaryotic or a eukaryotic cell.

### Claim 11 (depends on 1)

The method of claim 1, wherein the method comprises administering to the subject a combination of
(i) the immune checkpoint modulator; and
(ii) the microorganism comprising the nucleic acid.

### Claim 12 (depends on 11)

The method of claim 11, wherein the microorganism is selected from the group consisting of archaea, bacteria and eukaryotes.

### Claim 13 (depends on 11)

The method of claim 11, wherein the microorganism is selected from the group consisting of Escherichia spp., Salmonella spp., Yersinia spp., Vibrio spp., Listeria spp., Lactococcus spp., Shigella spp., Cyanobacteria, and Saccharomyces spp.

### Claim 14 (depends on 11)

The method of claim 11, wherein the microorganisms are provided as probiotics.

### Claim 15 (depends on 11)

The method of claim 11, wherein the virulence of the microorganism is attenuated.

### Claim 16 (depends on 11)

The method of claim 11, wherein the microorganism is a (recombinant) bacterium comprising the nucleic acid comprising the polynucleotide encoding the ATP hydrolyzing enzyme.

### Claim 17 (depends on 16)

The method of claim 16, wherein the bacterium heterologously expresses the ATP hydrolyzing enzyme.

### Claim 18 (depends on 16)

The method of claim 16, wherein the bacterium is selected from the group consisting of Gram-positive bacteria, Gram-negative bacteria and Cyanobacteria.

### Claim 19 (depends on 16)

The method of claim 16, wherein the bacterium is selected from the group consisting of Escherichia coli, Salmonella typhi, Salmonella typhimurium, Yersinia enterocolitica, Vibrio cholerae, Listeria monocytogenes, Lactococcus lactis and Shigella flexneri.

### Claim 20 (depends on 16)

The method of claim 16, wherein the bacterium is E. coli of the strain Nissle 1917.

### Claim 21 (depends on 1)

The method of claim 1, wherein the method comprises administering to the subject a combination of
(i) the immune checkpoint modulator; and
(ii) the viral particle comprising the nucleic acid.

### Claim 22 (depends on 21)

The method of claim 21, wherein the viral particle is a bacteriophage.

### Claim 23 (depends on 1)

The method of claim 1, wherein combination is comprised in a composition.

### Claim 24 (depends on 23)

The method of claim 23, wherein the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier, diluent and/or excipient.

### Claim 25 (depends on 23)

The method of claim 23, wherein the composition comprises a periplasmic extract of a bacterium comprising the nucleic acid comprising the polynucleotide encoding the ATP hydrolyzing enzyme.

### Claim 26 (depends on 1)

The method of claim 1, wherein the immune checkpoint modulator is an inhibitor of an inhibitory checkpoint molecule (checkpoint inhibitor).

### Claim 27 (depends on 26)

The method of claim 26, wherein the inhibitory checkpoint molecule is selected from the group consisting of A2AR, B7-H3, B7-H4, BTLA, CD40, CTLA-4, IDO, KIR, LAG3, PD-1, PDL-1, PD-L2, TIM-3, VISTA, CEACAM1, GARP, PS, CSF1R, CD94/NKG2A, TDO, TNFR, TIGIT and FasR/DcR3.

### Claim 28 (depends on 1)

The method of claim 1, wherein the immune checkpoint modulator is an inhibitor of A2AR, B7-H3, B7-H4, BTLA, CD40, CTLA-4, IDO, KIR, LAG3, PD-1, TIM-3, VISTA, CEACAM1, GARP, PS, CSF1R, CD94/NKG2A, TDO, TNFR, TIGIT or DcR3; or an inhibitor of a ligand thereof.

### Claim 29 (depends on 1)

The method of claim 1, wherein the immune checkpoint modulator is an inhibitor of the CTLA-4 pathway or the PD-1 pathway.

### Claim 30 (depends on 1)

The method of claim 1, wherein the immune checkpoint modulator is an inhibitor of PD-1, PD-L1, or PD-L2.

### Claim 31 (depends on 1)

The method of claim 1, wherein the combination further comprises
(a) an antigen or a fragment thereof comprising at least one antigenic epitope,
(b) a nucleic acid comprising a polynucleotide encoding the antigen or the fragment thereof comprising at least one antigenic epitope,
(c) a host cell comprising the nucleic acid comprising the polynucleotide encoding the antigen or the fragment thereof comprising at least one antigenic epitope,
(d) a microorganism comprising the nucleic acid comprising the polynucleotide encoding the antigen or the fragment thereof comprising at least one antigenic epitope, or
(e) a viral particle comprising the nucleic acid comprising the polynucleotide encoding the antigen or the fragment thereof comprising at least one antigenic epitope.

### Claim 32 (depends on 31)

The method of claim 31, wherein the combination comprises the host cell or the microorganism comprising the nucleic acid comprising the polynucleotide encoding the ATP hydrolyzing enzyme and the host cell or the microorganism comprising the nucleic acid comprising the polynucleotide encoding the antigen or the fragment thereof comprising at least one antigenic epitope.

### Claim 33 (depends on 31)

The method of claim 31, wherein the combination comprises the host cell or the microorganism (heterologously) expressing the ATP hydrolyzing enzyme and the host cell or the microorganism (heterologously) expressing the antigen or the fragment thereof comprising at least one antigenic epitope.

### Claim 34 (depends on 1)

The method of claim 1, wherein the combination is administered via a parenteral route of administration.

### Claim 35 (depends on 1)

The method of claim 1, wherein the combination is orally administered.

### Claim 36

A combination of
(i) an immune checkpoint modulator; and
(ii) an ATP hydrolyzing enzyme, wherein the ATP hydrolyzing enzyme is apyrase,
(iii) a nucleic acid comprising a polynucleotide encoding the ATP hydrolyzing enzyme,
(iv) a host cell comprising the nucleic acid,
(v) a microorganism comprising the nucleic acid, or
(vi) a viral particle comprising the nucleic acid.

### Claim 37

A kit comprising:
(i) an immune checkpoint modulator; and
(ii) (a) an ATP hydrolyzing enzyme,
(b) a nucleic acid comprising a polynucleotide encoding the ATP hydrolyzing enzyme,
(c) a host cell comprising the nucleic acid,
(d) a microorganism comprising the nucleic acid, or
(e) a viral particle comprising the nucleic acid,
wherein the ATP hydrolyzing enzyme is apyrase.
